PerkinElmer, Inc. (NYSE:PKI) Insider James M. Mock Sells 6,080 Shares

PerkinElmer, Inc. (NYSE:PKI) insider James M. Mock sold 6,080 shares of PerkinElmer stock in a transaction that occurred on Monday, September 20th. The shares were sold at an average price of $184.87, for a total transaction of $1,124,009.60. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Shares of PerkinElmer stock opened at $184.80 on Wednesday. PerkinElmer, Inc. has a 12-month low of $116.27 and a 12-month high of $191.07. The company has a market cap of $20.72 billion, a price-to-earnings ratio of 17.58, a PEG ratio of 0.50 and a beta of 1.10. The company has a current ratio of 2.01, a quick ratio of 1.56 and a debt-to-equity ratio of 0.55. The company’s 50-day moving average price is $179.57 and its 200-day moving average price is $153.32.

PerkinElmer (NYSE:PKI) last issued its quarterly earnings results on Sunday, July 25th. The medical research company reported $2.83 EPS for the quarter, beating analysts’ consensus estimates of $2.40 by $0.43. PerkinElmer had a net margin of 24.35% and a return on equity of 37.29%. The business had revenue of $1.23 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same period last year, the business earned $1.23 earnings per share. On average, sell-side analysts predict that PerkinElmer, Inc. will post 9.91 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 12th. Investors of record on Friday, October 22nd will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.15%. The ex-dividend date is Thursday, October 21st. PerkinElmer’s payout ratio is 3.37%.

PKI has been the topic of several recent research reports. Robert W. Baird reiterated an “outperform” rating and set a $172.11 target price (up from $150.00) on shares of PerkinElmer in a research report on Tuesday, July 27th. Royal Bank of Canada lifted their target price on shares of PerkinElmer from $48.00 to $49.00 and gave the stock an “outperform” rating in a research report on Monday, August 9th. Evercore ISI reiterated an “outperform” rating and set a $170.86 target price (down from $174.00) on shares of PerkinElmer in a research report on Tuesday, July 27th. Finally, Wolfe Research upgraded shares of PerkinElmer from a “market perform” rating to an “outperform” rating in a research report on Tuesday, June 15th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, PerkinElmer currently has a consensus rating of “Buy” and a consensus target price of $150.09.

A number of hedge funds have recently made changes to their positions in the stock. Parametric Portfolio Associates LLC lifted its stake in PerkinElmer by 18.3% in the second quarter. Parametric Portfolio Associates LLC now owns 416,532 shares of the medical research company’s stock worth $64,317,000 after acquiring an additional 64,339 shares during the period. B. Metzler seel. Sohn & Co. Holding AG lifted its position in PerkinElmer by 8.6% during the second quarter. B. Metzler seel. Sohn & Co. Holding AG now owns 4,734 shares of the medical research company’s stock valued at $731,000 after buying an additional 376 shares during the period. Colony Group LLC lifted its position in PerkinElmer by 9.2% during the second quarter. Colony Group LLC now owns 4,526 shares of the medical research company’s stock valued at $699,000 after buying an additional 382 shares during the period. Wells Fargo & Company MN lifted its position in PerkinElmer by 1.7% during the second quarter. Wells Fargo & Company MN now owns 503,269 shares of the medical research company’s stock valued at $77,709,000 after buying an additional 8,333 shares during the period. Finally, Worldquant Millennium Advisors LLC lifted its position in PerkinElmer by 0.9% during the second quarter. Worldquant Millennium Advisors LLC now owns 31,865 shares of the medical research company’s stock valued at $4,920,000 after buying an additional 293 shares during the period. 92.84% of the stock is owned by institutional investors.

PerkinElmer Company Profile

PerkinElmer, Inc engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment comprises of technologies that help life sciences researchers better understand diseases and develop treatments.

Further Reading: Index Funds

Insider Buying and Selling by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.